Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alyse Martin

Nurse Practitioner Jeffersonville, IN Nurse Practitioner

NPI 1740616192 CMS profile 10790999

255 Quartermaster Ct, Jeffersonville, IN 47130

Open in the dashboard

General payments

$3,574

153 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alyse Martin of Jeffersonville, IN is reported in the CMS Open Payments database as having received $3,574 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $821 30
2024 General $1,797 62
2023 General $545 34
2022 General $170 11
2021 General $240 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alyse Martin
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Alyse Martin were reported at $821. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Alyse Martin Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $240 $135 $40–$426 $132
2022 $170 $152 $48–$470 $149
2023 $545 $166 $54–$529 $160
2024 $1,797 $173 $55–$556 $164
2025 $821 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,495 45 payments
  2. AbbVie, Inc. $555 36 payments
  3. Novo Nordisk Inc $474 25 payments
  4. Lilly USA, LLC $352 16 payments
  5. Phathom Pharmaceuticals, Inc. $253 2 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $84 6 payments
  7. Sanofi-Aventis U.S. LLC $83 6 payments
  8. Exact Sciences Corporation $51 3 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $44 3 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $36 2 payments
  11. Other $146 9 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,574 153 payments
Products named General payments · program years 2021–2025
  1. AIRSUPRA $766 23 payments
  2. FARXIGA $616 14 payments
  3. BREZTRI $580 12 payments
  4. MOUNJARO $334 15 payments
  5. Ozempic $328 16 payments
  6. VOQUEZNA $253 2 payments
  7. VRAYLAR Neuroscience $231 16 payments
  8. RYBELSUS $173 13 payments
  9. UBRELVY $165 11 payments
  10. VRAYLAR Neuroscience $136 8 payments
  11. Other $902 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record